ATNX News and Press, Athenex Inc. From 11/09/21

BUFFALO, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a licensing agreement with th...

Athenex, Inc. (ATNX) Q3 2021 Earnings Conference Call November 5, 2021 08:00 ET Company Participants Caileigh Dougherty - Investor Relations Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Rudolf Kwan - Chief Medical Officer Dan Lang - President, Athenex Cell Thera...

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients...

Athenex (NASDAQ:ATNX): Q3 GAAP EPS of -$0.33 beats by $0.04. Revenue of $32.3M (-9.0% Y/Y) beats by $8.43M. Press Release 3Q product sales were $27.0M, up 9% year-over-year. For further details see: Athenex EPS beats by $0.04, beats on revenue

Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-year Company now expects ful...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Athenex (NASDAQ:ATNX) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.33 (+17.5% Y/Y) and the consensus Revenue Estimate is $23.87M (-32.7% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions an...

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide...

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide...

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr. Leonid Metelitsa in harn...